Back to search

University of Ioannina

Μελέτη της αγγειογένεσης και της λεμφαγγειογένεσης στο ακανθοκυτταρικό καρκίνωμα του στόματος, με ανοσοϊστοχημικές τεχνικές

Abstract

dc:description

Angiogenesis is the propelling force for tumor growth and metastatic dissemination in solidneoplasms. This process is tightly controlled by numerous positive and negative angiogenic factorsand their receptors, the interaction of which regulates the cascades enabled in tumorneovascularization. Among the factors causing tumor angiogenesis, vascular endothelial growth factor (VEGF) is considered as a leading candidate. VEGF induces the proliferation, differentiation, and migration of vascular endothelial cells, increases the permeability of the capillaries, and also enhances the survival of endothelial cells by preventing their apoptosis. It has been proposed that the quantification of angiogenesis by the assessment of microvascular density (MVD), as well as theevaluation of VEGF immunohistochemical expression may have prognostic value in a number ofmalignancies, including head and neck squamous cell carcinoma (HNSCC). Lymph node metastasis is a frequent reason for adverse clinical outcome in many epithelial neoplasms, including HNSCC. The mechanisms underlying the capability of epithelial neoplasms to metastasize via lymphatic vessels have not yet been fully elucidated. There is great debate about whether cancer cells can metastasize by expansion and invasion of pre-existing peritumoral lymphatics or by the formation and invasion of new lymphatics within tumours (lymphangiogenesis). Currently, researchers probe into the mechanisms of lymphangiogenesis. Central to these efforts was the discovery of lymphatic endothelium markers, such as LYVE-1, the antibody against podoplanin, D2-40,prox-l andVEGFR-3.We aimed to study angiogenesis and lymphangiogenesis in 81 formalin-fixed, paraffin embedded archival tissue blocks of HNSCC specimens, applying immunohistochemical techniques. We evaluated the expression of VEGF and its receptors (VEGFR-1 and VEGFR-2) by squamouscancer cells and assessed MVD with the use of both the traditional endothelial markers CD31 andCD34, as well as with the use of the newly proposed marker CD 105 (endoglin). We also addressed the impact of hypoxia-induced angiogenic pathway by examining the expression of HIF-la. Furthermore, we studied lymphangiogenesis, using immunostaining for the specific lymphatic endothelium marker podoplanin, assessed intratumoral and peritumoral lymphatic density (ILD and PLD), and also quantified lymphatic invasion. Active lymphangiogenesis was examined with double staining with podoplanin and the cell proliferation marker Ki-67. We also addressed the diagnostic accuracy of two of the so called "specific lymphatic endothelial markers", podoplanin and D2-40. Moreover, we assessed the expression of VEGF-C and its possible correlation with COX-2 expression, in order to investigate the impact of the prostaglandin pathway in lymphangiogenesis. Finally, we evaluated the correlation between cell-cell adhesion and lymphangiogenesis by examining the expression of dysadherin and E-cadherin along with lymphatic density. Dysadherin is a recently characterized cancer-associated cell membrane glycoprotein that acts as an "anti-adhesion molecule" by deactivation of E-cadherin in a posttranscriptional manner. VEGF overexpression was associated with advanced clinical stage, positive surgical margins and worse overall survival. The prognostic significance of VEGF in HNSCC was further supported bythe synthesis of the results of all the studies addressing this issue, with the method of meta-analysis. The estimated risk of death in 2 years was 1.88 fold higher in the VEGF-positive patients (95% CI: 1.43-2.45, p<0.001, random effects calculations). VEGF overexpression was also significantly associated with higher MVD, when the last was determined with CD 105. CD 105 was intensively expressed in intratumoral blood vessels, whilst vessels at the adjacent normal mucosa were only rarely expressing this marker. MVD determined with CD105 (but not with CD34 or CD31) was associated with worse overall survival in our cohort of patients. The investigation for VEGF receptors revealed the existence of these receptors in cancer cell membranes, besides vascular endothelium. High expression of VEGF was strongly correlated with high expression of VEGFR-2 (but not VEGFR-1) on the cancer cells (pO.001). The co-overexpression of both the protein and VEGFR-2 was associated with higher tumor proliferation rate, as indicated with ki-67 (p<0.001). These results suggest that an autocrine VEGF loop, mediated via VEGFR-2, probably exists in HNSCC. Squamous cancer cells probably produce VEGF not only to induce neoplastic angiogenesis, but also to enhance their uncontrolled proliferation. Studying the hypoxia-induced tumor angiogenic pathway, we observed a statistically significant association between HIF-la and VEGF expression in tumors located in the lower lip, but not in the rest. These findings support the hypothesis that tumor angiogenesis is closely related, but not strictly dependent, on the hypoxic conditions of tumors' microenvironment. Double staining with podoplanin / ki-67 revealed the existence of proliferating intratumoral lymphatics, in which tumour emboli were occasionally observed. High ILD and PLD were both significantly associated with the presence of lymph node metastasis (x2 test, ρ < 0.001 and ρ = 0.007, respectively) and there was a significant correlation between high ILD and lymphatic invasion. Patients with higher intratumoral lymphatic density exhibited shorter overall survival. These results indicate that lymphangiogenesis indeed occurs in HNSCC; that newly formed vessels are targets of invasion by cancer cells; and that intratumoral lymphatic density might be used as a criterion to separate patients at higher risk of an adverse clinical outcome. Reservations about the existence of lymphangiogenesis in tumors are boosted by the absence of quantitative data about the diagnostic accuracy of lymphatic endothelium markers. We therefore compared the diagnostic accuracy of the antibody against podoplanin and the commercially available D2-40, employing Bayesian statistics to account for the absence of a gold standard. Both antibodies had extremely high specificity (99.7% and 98.8% for podoplanin and D2-40, respectively) and very high sensitivity (92.6% and 97.3% for podoplanin and D2-40, respectively). These results suggest that both antibodies are excellent lymphatic endothelium markers. Results for VEGF-C revealed that the expression of this protein marches with COX-2 overexpression (p<0.001), and both are strongly correlated with the presence of lymph node metastasis (p<0.001). Studies performed after the publication of our results confirmed these observations and support the hypothesis for a prostaglandin-mediated lymphangiogenic pathway, in which COX-2 stimulates VEGF-C up-regulation. Finally, the examination of cell-cell adhesion along with the micro-lymphovasculature environment in HNSCC revealed, besides an impressive reverse association between increased dysadherin expression and decreased E-cadherin expression (x"pO.001), a strong association between higher dysadherin expression with high ILD (x~, ρ = 0.001) and the presence of lymph node metastasis (x2 p=0.02). Surprisingly, dysadherin-positive cancer cellsusually gathered around areas of high intratumoral lymphatic vessel concentration, surrounding andinvading small intratumoral lymphatics. Thus, the loss of intercellular adhesiveness and increaseddysadherin expression seems to be related to lymphangiogenesis in HNSCC. In summary, angiogenesis and lymphangiogenesis seem to play a crucial role in HNSCC. Further understanding of the mechanisms underlying these procedures will aid the incorporation of novel prognostic tools into clinical practice and help the development of drugs targeting several of their critical steps in order to improve patients' outcome.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2006

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Κύζας, Παναγιώτης
  • Kyzas, Panagiotis

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/21822

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Κύζας, Παναγιώτης; Kyzas, Panagiotis. Μελέτη της αγγειογένεσης και της λεμφαγγειογένεσης στο ακανθοκυτταρικό καρκίνωμα του στόματος, με ανοσοϊστοχημικές τεχνικές. University of Ioannina, 2006. http://hdl.handle.net/10442/hedi/21822